Navigation Links
Jean-Pol Tassin wins the 2009 ECNP Neuropsychopharmacological Award
Date:9/23/2009

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Jean-Pol Tassin as the recipient of the 2009 ECNP Neuropsychopharmacology Award in Basic Science Research in recognition of his pioneering and innovative research into the neurochemical basis of substance addiction.

The ECNP Neuropsychopharmacology Award recognises outstanding research in the field of neuropsychopharmacology and its closely related disciplines. Granted annually, the award alternates between basic science and clinical research and is accompanied by a prize of EUR 20,000. Jean-Pol Tassin Tassin is the award's 31st recipient.

Jean-Pol Tassin, currently team leader at the Collge de France's Molecular Genetic, Neurophysiology and Behaviour Laboratory in Paris, was drawn to addiction by his early research on nerve terminals in the prefrontal cortex and the effects of stress and long-term isolation on the meso-cortical pathway. Moving to studies on the impact of psychostimulants on cortical and sub-cortical neurons, his critical insight was to connect the disruption of nonadrenaline and serotonin neuron interaction with addictive behaviour. Jean-Pol Tassin's research showed how these neurons, when exposed to repeated psychostimulant abuse, become 'uncoupled,' thereby inducing distress, or withdrawal, for which further administrations of the drug are needed to achieve relief. Later refinements to this groundbreaking model have highlighted the key role played in tobacco addiction by monoamine inhibitors present in cigarettes.

Presenting the award at the 22nd ECNP Congress in Istanbul, the chairman of the ECNP Award Jury 2009, Tomas Hkfelt of the Karolinska Institute in Stockholm, commended Tassin's scientific originality as well as his landmark contribution to our understanding of this critical public health concern.


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
431-405-5734
European College of Neuropsychopharmacology
Source:Eurekalert

Page: 1

Related biology news :

1. ESF EURYI award winner aims to stop cancer cells reading their own DNA
2. The American Society of Plant Biologists announces 2007 awards
3. Minimally invasive heart surgery research wins NIH award
4. 12 McGill researchers awarded Canada Research Chairs
5. Herr receives Heinz Award for Technology, the Economy and Employment
6. Singapore National Science and Technology Awards
7. RSC Project Prospect scoops prestigious award
8. Springer book wins Quality of Communication Award
9. Homeland Security awards 2 grants to Rutgers for nuclear threat detection
10. NIH awards nearly $23M to University of Chicago for translational research
11. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
Breaking Biology Technology: